The activity of this inhibitor towardother kinases offered the opportunity to study the effect of DYRK1Aand GSK3β kinases on the NFAT pathway, allowing us to predicta positive effect toward β-cell expression and diabetes. Here, GSK3B is linked to diabetes mellitus.